Financing, Debt Capital Markets - Depositories, Real Estate & Financial Services

Regent Capital Corporation

07/21
|
$20.0 Million
Piper Sandler served as sole placement agent for Regent Capital Corporation on a 4.00% fixed-to-floating rate subordinated notes offering due in 2031
Sub-Type
Subordinated Notes
Sector
Financial Services
Sub-Sector
Depositories

Related Transactions

All Transactions
$42.0 Million
Trinitas
Trinitas Capital Management, LLC
Senior Unsecured Notes Offering
Sole Placement Agent
$70.0 Million
CereVasc
Bain
Xontogeny
CereVasc, Inc.
CereVasc, Inc. has received a Series B Financing from Bain Capital Life Sciences and Perceptive Xontogeny Venture Fund (PXV)

Financial Advisor
$50.0 Million
Legion
Riverwood
Legion Technologies, Inc.
Legion Technologies, Inc. has received a growth investment from Riverwood Capital Management L.P.
Financial Advisor
$201.2 Million
Nurix Inc.
Nurix Inc.
Active Bookrunner
$150.0 Million
Blue Ridge Bankshares
Blue Ridge Bankshares, Inc.
PIPE
Sole Placement Agent
$200.0 Million
Praxis Precision Medicines
Praxis Precision Medicines, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$100.0 Million
Boundless Bio, Inc.
Boundless Bio, Inc.
Initial Public Offering
Active Bookrunner
$75.0 Million
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$600.0 Million
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$43.0 Million
CSC
CSC Leasing Company, Inc
Reopened Senior Unsecured Notes
Sole Placement Agent
$50.0 Million
Unicycive
Unicycive Therapeutics
PIPE
Joint Placement Agent
$40.0 Million
Skye Bioscience
Skye Bioscience
PIPE
Sole Placement Agent
$100.0 Million
Ventyx Biosciences
Ventyx Biosciences
PIPE
Joint Placement Agent
$30.0 Million
milestone
Milestone Pharmaceuticals, Inc.
Confidentially Marketed Follow-On Offering
Left Bookrunner
$1.1 Billion
Applovin
Applovin
Confidentially Marketed Follow-On Offering
Passive Bookrunner
$201.5 Million
New Amsterdam Pharma N.V.
New Amsterdam Pharma N.V.
Confidentially Marketed Follow-On Offering
Active Bookrunner

© 2024 Piper Sandler Companies. Since 1895. All rights reserved.